Parkinson’s Treatment Market size was valued at USD 4,482.4 million in 2021, growing at a CAGR of 12.4% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by drug class and by distribution channel. By drug class, the global parkinson’s treatment market has been segmented into Monoamine Oxidase Inhibitors (MAO), Dopamine Precursors, Catechol-o-methyltransferase Inhibitors (COMT), Peripheral Decarboxylase Inhibitors, Others (Anticholinergics, Antihistaminics). The Peripheral Decarboxylase Inhibitors segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. It is attributed to the potency of the drug than other class of drugs. Based on distribution channel, the global parkinson’s treatment market is segmented into Hospital Pharmacies, Online Pharmacies, Retail Pharmacies. Among these, the Hospital Pharmacies segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to precision business insights. It is due to the large patient base in the hospital which makes high demand in hospital pharmacies. Also, the growing number of patient visits to the hospital due to the availability of diagnostic laboratories and skilled professionals and doctors. Parkinson’s disease is the chronic, progressive neurodegenerative disorder which can be characterized by rigidity, tremors, postural instability and bradykinesia (slowness of movement). In Parkinson’s disorder patients can also experience the significant non-motor symptoms like changes in the sleep disturbances, autonomic erectile dysfunction and cognition and mood swings. The condition is attributed to the degeneration of the dopamine-producing cells of the substantia nigra.
In Sept 2022, Kyowa Kirin announced the launch of new assets to help educate and empower adult patients to talk to their PD care team.
In Oct 2022, Muna Therapeutics announced that it has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).